In Vivo Labeling and Enumeration of Circulating Tumor Cells with a Folate-Receptor Targeted Molecular Probe

2021 ◽  
Author(s):  
Joshua Pace ◽  
Fernando Ivich ◽  
Roshani A. Patil ◽  
Srinivasarao Madduri ◽  
Mansoor M. Amiji ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Folate Receptor ◽  
Molecular Probe ◽  
In Vivo Labeling

scholarly journals Fluorescence Labeling of Circulating Tumor Cells with a Folate Receptor-Targeted Molecular Probe for Diffuse In Vivo Flow Cytometry

2020 ◽  
Vol 22 (5) ◽  
pp. 1280-1289 ◽  
Author(s):  
Roshani A. Patil ◽  
Madduri Srinivasarao ◽  
Mansoor M. Amiji ◽  
Philip S. Low ◽  
Mark Niedre
Keyword(s):  
Flow Cytometry ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Folate Receptor ◽  
Molecular Probe ◽  
Fluorescence Labeling ◽  
In Vivo Flow Cytometry

scholarly journals Fluorescence Labeling of Circulating Tumor Cells with Folate Receptor Targeted Molecular Probes for Diffuse In Vivo Flow Cytometry

2020 ◽  
Author(s):  
Roshani Patil ◽  
Madduri Srinivasarao ◽  
Mansoor Amiji ◽  
Philip S. Low ◽  
Mark Niedre
Keyword(s):  
Flow Cytometry ◽  
Animal Models ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Whole Blood ◽  
Folate Receptor ◽  
Molecular Probes ◽  
Cell Surface Receptor

AbstractPurposeWe recently developed a new instrument called ‘diffuse in vivo flow cytometry’ (DiFC) for enumeration of rare fluorescently-labeled circulating tumor cells (CTCs) in small animals without drawing blood samples. Until now, we have used cell lines that express fluorescent proteins, or were pre-labeled with a fluorescent dye ex-vivo. In this work, we investigated the use of two folate receptor (FR)-targeted fluorescence molecular probes for in vivo labeling of FR+ CTCs for DiFC.MethodsWe used EC-17 and Cy5-PEG-FR fluorescent probes. We studied the affinity of these probes for L1210A and KB cancer cells, both of which over-express FR. We tested the labeling specificity in cells in culture in vitro, in whole blood, and in mice in vivo. We also studied detectability of labeled cells with DiFC.ResultsBoth EC-17 and Cy5-PEG-FR probes had high affinity for FR+ CTCs in cell culture in vitro. However, only EC-17 had sufficient specificity for CTCs in whole blood. EC-17 labeled CTCs were also readily detectable in circulation in mice with DiFC.ConclusionsThis work demonstrates the feasibility of labeling CTCs for DiFC with a cell surface receptor targeted probe, greatly expanding the utility of the method for pre-clinical animal models. Because DiFC uses diffuse light, this method could be also used to enumerate CTCs in larger animal models and potentially even in humans.

scholarly journals In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry

2007 ◽  
Vol 104 (28) ◽  
pp. 11760-11765 ◽  
Author(s):  
W. He ◽  
H. Wang ◽  
L. C. Hartmann ◽  
J.-X. Cheng ◽  
P. S. Low
Keyword(s):  
Flow Cytometry ◽  
Tumor Cells ◽  
Circulating Tumor Cells

scholarly journals Construction and Evaluation of the Tumor-Targeting, Cell-Penetrating Multifunctional Molecular Probe iCREKA

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Li-juan Wang ◽  
Hong-sheng Li ◽  
Quan-shi Wang ◽  
Hu-bing Wu ◽  
Yan-jiang Han ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Tumor Targeting ◽  
Cyclic Peptide ◽  
Tumor Imaging ◽  
Tumor Stroma ◽  
Molecular Probe ◽  
Fluorescence Signal ◽  
Glioma Tumor

A novel tumor stroma targeting and membrane-penetrating cyclic peptide, named iCREKA, was designed and labeled by fluorescein isothiocyanate (FITC) and positron emitter 18F to build the tumor-targeting tracers. The FITC-iCREKA was proved to have significantly higher cellular uptake in the glioma U87 cells in the presence of activated MMP-2 than that in absence of activated MMP-2 by cells fluorescence test in vitro. The tumor tissue fluorescence microscope imaging demonstrated that FITC-iCREKA accumulated in the walls of the blood vessels and the surrounding stroma in the glioma tumor at 1 h after intravenous injection. While at 3 h after injection, FITC-iCREKA was found to be uptaken in the tumor cells. However, the control FITC-CREKA can only be found in the tumor stroma, not in the tumor cells, no matter at 1 h or 3 h after injection. The whole-animal fluorescence imaging showed that the glioma tumor could be visualized clearly with high fluorescence signal. The microPET/CT imaging further demonstrated that 18F-iCREKA could target U87MG tumor in vivo from 30 min to 2 h after injection. The present study indicated the iCREKA had the capacity of tumor stroma targeting and the membrane-penetrating. It was potential to be developed as the fluorescent and PET tracers for tumor imaging.

scholarly journals Functional Studies on Viable Circulating Tumor Cells

2016 ◽  
Vol 62 (2) ◽  
pp. 328-334 ◽  
Author(s):  
Klaus Pantel ◽  
Catherine Alix-Panabières
Keyword(s):  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cancer Diagnostics ◽  
Published Data ◽  
Liquid Biopsies ◽  
In Vivo Models ◽  
Functional Studies

AbstractBACKGROUNDResearch on circulating tumor cells (CTCs) as new biomarkers has received great attention over the past decade. In particular, the capture and analysis of CTCs as “liquid biopsies” provides the possibility to avoid invasive tissue biopsies, with obvious implications in cancer diagnostics.CONTENTThe focus of this review is to describe and discuss how functional studies on viable CTCs can enlarge the spectrum of applications of liquid biopsies, with emphasis on breast, prostate, colon, and lung cancer as the major tumor entities in industrialized countries. The low number of CTCs in the peripheral blood of most cancer patients makes challenging the in vitro culture of CTCs. Epithelial tumor cells are difficult to culture, even when starting with millions of tumor cells. Recently, several groups have achieved important advances in the in vitro and in vivo expansion of CTCs from cancer patients at very advanced stages with higher amounts of CTCs. Here, we present current technologies to enrich and detect viable human CTCs, including positive and negative enrichment strategies that are based on antigen expression and physical properties of CTCs. We also discuss published data about functional studies on CTCs that use in vitro and in vivo models.SUMMARYFunctional analyses on CTCs offer the possibility to identify the biological properties of metastatic cells, including the identification of metastasis-initiating cells. Moreover, CTC-derived cell lines and xenografts might reveal new therapeutic targets and can be used for drug screening.

Sign in / Sign up

Export Citation Format

Share Document